Trial0
Sign inMap the options

Conditions · Alzheimer's disease & early-stage dementia

Alzheimer's & early-stage dementia frontier treatment options

Anti-amyloid and anti-tau programs, and most disease-modifying trials, publish narrow windows — typically MCI to mild stage with biomarker confirmation. The map shows which published windows a profile plausibly fits.

Map this patient’s options

By continuing, you ask Trial0 to email you when new trials match this condition. Unsubscribe any time.

Open options now (1154 open studies; showing 30)

Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗

Narrow by phase or treatment type

Phase 1Phase 2Phase 3DrugBiological & vaccineDeviceProcedure & surgicalRadiation

By state in the United States

AlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahVermontVirginiaWashingtonWest VirginiaWisconsinWyomingDistrict of Columbia

By country

Each country page filters the live registry to listed sites in that country and links to the relevant official national or regional registry for additional local discovery.

United StatesCanadaUnited KingdomAustraliaNew ZealandIrelandFranceGermanyNetherlandsBelgiumSpainItalySwedenDenmarkNorwayFinland

Common questions

How does Trial0 find Alzheimer's disease & early-stage dementia options?
Every list on this page is a live query of ClinicalTrials.gov (API v2) for open interventional trials and expanded-access programs, refreshed at most hourly. Nothing is hand-curated or cached beyond that window.
Does a match mean the patient is eligible?
No. Structured registry fields (age, sex, status, phase) give firm matched/not-matched states; free-text criteria can only be checked for mentions, which are signposts to verify with the site. Only the trial site can determine actual eligibility.
What does the verified site data mean?
Registry recruiting status is often stale. Trial0 separately records first-hand observations — whether a specific site is really recruiting and whether the investigator accepts outside referrals — each stamped with the date it was verified.
What does access help cost?
The eligibility map and new-trial alerts are free. Pro is $49/month or £49/month and covers contact research, draft preparation and approval-first outreach. Trial0 never takes a commission from a provider.

How to use this Alzheimer's disease & early-stage dementia trial page

This page is refreshed from live registry data and shows currently open interventional studies and expanded-access programmes. Trial records are leads, not a clinical recommendation.

Use the full matcher to add age, treatment history, biomarkers and a location. It labels published criteria honestly: a mention in free text is a prompt to verify, not a finding of eligibility.

Free alerts help you notice new registry entries. Pro can research a contact and prepare outreach, but Trial0 asks for approval before contacting each trial.

Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors. Data refreshed at most every 1 hour(s).